To include your compound in the COVID-19 Resource Center, submit it here.

Circuit logic

How BlackThorn is taking an algorithmic approach to neurological drug development

BlackThorn Therapeutics Inc. has begun the first of a series of studies that will test whether it can solve a tough problem in neurological drug development: the tendency of heterogeneity among patients with the same clinical diagnosis to mask the effects of compounds in clinical trials.

The company has developed an informatics platform called INFORM to identify the neural circuits that drive neurobehavioral symptoms, select targets expressed within those circuits, and identify patient populations likely to respond to therapies against those targets.

The platform uses algorithms to analyze structural and functional MRI imaging along with observational

Read the full 940 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers